A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
Clinical trial NCT03331731 · UNKNOWN
Trial details
- NCT number
- NCT03331731
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-29
- Primary completion
- 2023-02-16
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.